Bristol-Myers Squibb Company(BMY)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Latest News & Analysis
Bristol-Myers Squibb (BMY): Dividend Safety, Patents, and FDA
Bristol-Myers Squibb (BMY) navigates patent expirations, tariff threats, and market volatility. A data-driven analysis of BMY's financials and FDA approvals.
Bristol Myers Squibb (BMY): Opdivo, Dividends, and Market Challenges
Bristol Myers Squibb (BMY) navigates market volatility with Opdivo's growth, cost cuts, and dividend focus amidst revenue decline forecasts. Key insights for investors.
Bristol-Myers Squibb (BMY): Opdivo's European Approval, Debt Concerns, and Investor Outlook
Bristol-Myers Squibb (BMY) navigates Opdivo's European expansion amid debt concerns. A defensive stock with value potential, yet faces market volatility. Investors should weigh these factors.
Bristol-Myers Squibb (BMY): Navigating Challenges and Driving Growth
Bristol-Myers Squibb (BMY) faces Revlimid LOE but focuses on growth portfolio expansion and cost-cutting. Breyanzi's EU approval is a key growth driver.
Bristol-Myers Squibb (BMY): Breyanzi Approval, 2seventy Bio Deal & Dividend Strategy
Bristol-Myers Squibb (BMY) navigates acquisitions, regulatory approvals, and market dynamics. A look at Breyanzi's approval, the 2seventy bio deal, and dividend strategy.
Bristol-Myers Squibb (BMY): Acquisition Strategy, Dividend Dilemma, and Growth Prospects
BMY faces a complex landscape with its acquisition of 2seventy bio under scrutiny, Sotyktu showing promise, and questions arising over dividend sustainability.
Bristol Myers Squibb (BMY): Oncology Strategy and Financial Outlook
Bristol Myers Squibb (BMY) navigates strategic acquisitions, clinical trial successes, and cost-cutting to maintain market position and dividend sustainability.
Bristol-Myers Squibb (BMY): Navigating Revenue Transition and Growth
Bristol-Myers Squibb (BMY) navigates revenue transition with new drugs, cost cuts. Sotyktu's success & Opdivo's EU approval offer growth. A defensive, high-yield dividend stock.
Bristol-Myers Squibb (BMY): Opdivo Approval, Acquisitions, and Market Outlook
Bristol-Myers Squibb (BMY) navigates patent expirations with strategic acquisitions and cost-cutting. Opdivo's EU approval and pipeline expansion offer growth potential.
Bristol-Myers Squibb (BMY): Navigating Patent Expirations and Pipeline Development
Bristol-Myers Squibb (BMY) navigates patent expirations, pipeline development, and a shifting market. FDA reviews, oncology advancements, and dividend strategies shape its future.
Bristol Myers Squibb (BMY): FDA Approvals, Oncology Growth, and Dividend Analysis
Bristol Myers Squibb (BMY) navigates patent expirations, oncology growth, and strategic collaborations. FDA actions and dividend appeal shape investor attention.
Bristol-Myers Squibb (BMY): Oncology Pipeline, Dividend Strategy, and Future Outlook
Bristol-Myers Squibb (BMY) navigates oncology advancements, pipeline challenges, and financial pressures. Strategic partnerships and innovation balance stability. Market rotation favors dividend stocks.
Bristol Myers Squibb: Navigating Patent Cliffs, Driving Growth
Bristol Myers Squibb navigates patent expirations with new drugs, strategic partnerships, and cost cuts. FDA reviews Opdivo/Yervoy, Breyanzi sales surge, and BioArctic collaborates.
Bristol Myers Squibb: Pipeline Developments, Market Impact, and Industry Trends
Bristol Myers Squibb (BMY) is expanding its pipeline with strategic collaborations and robust drug data amidst competitive industry challenges.
Bristol Myers Squibb: Pipeline Progress & Patent Cliff Challenges
Bristol Myers Squibb navigates pipeline advancements amid patent cliff challenges, with Opdivo, Sotyktu, and Breyanzi updates influencing investor sentiment.
Bristol Myers Squibb: Market Developments and Strategic Outlook
Explore the latest developments, trials, and licensing agreements at BMY, impacting its competitive landscape and market outlook.
Bristol Myers Squibb: Pipeline Progress Amidst Patent Expiration Challenges
Intraday update on BMY’s breakthroughs in immuno‐oncology, robust pipeline data, and strategic financial moves.
Bristol-Myers Squibb Strategic Reorganization and Pipeline Developments
Detailed analysis of BMY's reorganization, pipeline developments, and financial challenges amid patent expirations and a strong dividend strategy.